Postmarketing use of enfuvirtide in veterans: Provider compliance with criteria for use, overall efficacy, and tolerability

Annals of Pharmacotherapy

Volumn 42, Issue 11, 2008, Pages 1573-1580

  Belperio, Pamela S ^a,b,d   Mole, Larry A ^c   Halloran, James ^c   Boothroyd, Derek B ^c   Thomas, I Chun ^c   Backus, Lisa I ^c  

^a Center for Quality Management in Public Health   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Compliance; Enfuvirtide; HIV; Outcome

Indexed keywords

ENFUVIRTIDE;

ADULT; AGED; ARTICLE; BRONCHITIS; CD4+ T LYMPHOCYTE; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION; VETERAN; VIRUS LOAD; VOMITING;

ADULT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PEPTIDE FRAGMENTS; PHYSICIAN'S PRACTICE PATTERNS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 55949109603     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L265     Document Type: Article

References (19)

1. Product information. Fuzeon (enfuvirtide) for Injection. Nutley, NJ: Roche Laboratories, Inc. and Trimeris Inc., January 2007.
2. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85.
3. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95.
4. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40:404-12.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008:1-128. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescent-GL.pdf (accessed 2008 Feb17).
6. Gathe J, Cooper DA, Farthing C, et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006;43:1337-46.
7. Cahn P, Villacian J, Lazzarin A, et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006;43:1347-56.
8. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-78.
9. Food and Drug Administration. Antiviral Drugs Advisory Committee Briefing Document. Maraviroc Tablets NDA 22-128. April 24, 2007. www.fda.gov/ohrms/ dockets/ac/cder07.htm#AntiviralDrugs (accessed 2008 Feb 22).
10. Cooper D, Gatell J, Rockstroh J, et al. 48-Week results from BENCHMRK-1, a phase 3 study of raltegravir in patients failing ART with triple-class resistant HIV-1 (abstract 788). In: Programs and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3-6, 2008.
11. Steigbigel R, Kumar P, Eron J, et al. 48-Week results of BENCHMRK-2, a phase 3 study of raltegravir in patients failing ART with triple-class resistant HIV-1 (abstract 789). In: Programs and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3-6, 2008.
12. Cahn P, Haurich R, Leider J, et al. Pooled 24-week results of DUET-1 and DUET-2: TMC125 (etravirine) versus placebo in treatment-experienced HIV-1 infected patients (abstract H-717). In: Programs and Abstracts of the 47th International Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 17-20, 2007.
13. Raffi F, Katlama C, Saag MS, et al. Week 12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 Versus Optimized Regimen Only (TORO) trials. Clin Infect Dis 2006;42:870-77.
14. Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005;40:413-21.
15. Lalezari JP, Eron JJ, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003; 17:691-8.
16. Witek J, Rockstroh J, Donatacci L, et al. Adherence to enfuvirtide and to background antiretroviral therapy over 48 weeks and its impact on treatment efficacy (abstract We PeB5822). In: Program and Abstracts of the 15th International AIDS Conference. Bangkok, Thailand, July 11-16, 2004.
17. Cohen CJ, Dusek A, Green J, Johns EL, Nelson E, Recny MA. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS 2002;16:327-35.
18. Jamjian MC, McNicholl IR. Enfuvirtide: first fusion inhibitor for treatment of HIV infection. Am J Health Syst Pharm 2004;61:1242-7.
19. Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 2004;18:1137-46.